glp 1 losing effectiveness Key Facts GPs Should Know About GLP-1 Analogs How FDA Crackdowns Are Affecting

These findings highlight the need for prospective studies that integrate longitudinal assessments of weight, thyroid function, and levothyroxine dosing to validate these results and clarify the mechanisms linking GLP-1RA use to cardiovascular outcomes, including atrial fibrillation/flutter and stroke

At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37% higher than in users of so-called SGLT-2 drugs and 68% higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ

Clinical Screening: This necessitates rigorous cardiovascular screening and monitoring before and during treatment, particularly for patients with pre-existing cardiac rhythm issues

Stress, cortisol, and other appetite-related hormones: Prospective prediction of 6-month changes in food cravings and weight